Abstract: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.
Type:
Grant
Filed:
September 12, 2002
Date of Patent:
November 1, 2005
Assignee:
ViRexx Medical Corporation
Inventors:
Antoine Noujaim, Roland H. Person, Michael W. Stewart
Abstract: The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.
Type:
Grant
Filed:
November 12, 1999
Date of Patent:
May 3, 2005
Assignee:
ViRexx Medical Corporation
Inventors:
Michael William Stewart, Roland Henryk Person, Antoine Noujaim